Johnson & Johnson has filed a motion for order to show cause asking a federal judge to dismiss all 67,000 pending talcum powder lawsuits in the multidistrict litigation, calling the situation a "stunning turn of events" after lead plaintiffs' counsel withdrew the two "marquee" specific causation experts underpinning the litigation. The move is one of the most aggressive procedural maneuvers in recent MDL history and carries immediate consequences for plaintiff firms, claimants, and the broader talc tort landscape.
What Happened
According to Law.com, Johnson & Johnson filed a motion for order to show cause in the talc multidistrict litigation, arguing that the entire MDL has been fatally undermined. The company's argument centers on the fact that lead plaintiffs' counsel withdrew their two primary specific causation experts — described in the filing as the "marquee" witnesses that were expected to tie talcum powder use to cancer diagnoses across the plaintiff population.
Without those experts, J&J contends, plaintiffs cannot satisfy the causation burden required to move cases forward, and the court should therefore order a potential dismissal of all approximately 67,000 pending lawsuits.
The motion was filed on or around July 16, 2026. Law.com characterized the development as a "stunning turn of events" — language that signals how unexpected this procedural shift is even to veteran MDL observers.
Background
The talcum powder MDL has been one of the largest and most contentious mass tort litigations in the United States for years. Tens of thousands of plaintiffs — predominantly women — allege that long-term use of Johnson & Johnson talc-based products, including its iconic Baby Powder, caused ovarian cancer and mesothelioma. The scientific debate has centered on whether talc products were contaminated with asbestos and whether that contamination is capable of causing the cancers alleged.
J&J has repeatedly attempted to resolve or neutralize the litigation through extraordinary measures. The company pursued a controversial bankruptcy strategy using a subsidiary — sometimes called a "Texas Two-Step" maneuver — that sought to funnel all talc claims into a Chapter 11 proceeding. Federal courts ultimately rejected that approach, leaving the MDL as the primary litigation venue.
In MDL proceedings, specific causation experts are critical. These witnesses are tasked with establishing, on a case-by-case or representative basis, that the defendant's product caused the particular type of cancer a plaintiff developed. The withdrawal of the two lead specific causation experts is therefore not a minor procedural hiccup — it strikes at the evidentiary core of thousands of individual claims.
It is not yet publicly clear why lead plaintiffs' counsel withdrew those experts, whether replacement experts are being identified, or how the presiding judge will respond to J&J's motion. Those details are expected to emerge as the court sets a briefing schedule and response deadline.
What This Means for Plaintiff Firms
An Inflection Point for Active Docket Management
For plaintiff firms carrying talc cases on their dockets, this motion demands immediate attention. A dismissal order — even a conditional one requiring plaintiffs to show cause — could trigger a cascade of case management deadlines, fee implications, and client communication obligations. Firms should be coordinating with MDL leadership counsel and monitoring the court's response in real time.
Intake Dynamics Are Shifting
Paradoxically, aggressive defense maneuvers in high-profile MDLs often drive short-term spikes in claimant awareness. When J&J's bankruptcy strategy failed and litigation resumed in open court, intake demand for talc cases rose measurably as news coverage reached potential claimants who had been following the story. The same dynamic is likely here: coverage of a motion to dismiss 67,000 lawsuits will reach a broad audience, and some of that audience will include women with unrepresented ovarian cancer or mesothelioma claims who are now prompted to act.
The question for advertising-side strategy is timing and message. Plaintiff firms that are actively accepting talc cases should be positioned to capture that awareness spike with clear, factual messaging — without overstating the current state of the litigation. Firms that have paused intake should evaluate whether the expert withdrawal changes their risk calculus before resuming campaigns.
Causation Expert Strategy Is Now a Competitive Differentiator
The withdrawal of the MDL's lead specific causation experts does not necessarily extinguish individual claims, particularly those filed or retained outside the MDL's central expert infrastructure. Plaintiff firms that have independently secured robust causation expert support — or that move quickly to identify qualified replacements — will be in a materially stronger position than those relying entirely on MDL-wide expert tracks. This development underscores why plaintiff-side infrastructure and expert relationships matter beyond the MDL leadership structure.
Advertising Spend Efficiency Will Be Closely Watched
For firms running paid talc campaigns, the next several weeks represent a high-uncertainty window. The news cycle will generate organic awareness, but the litigation outcome is genuinely uncertain. Agencies and firms should be monitoring cost-per-lead trends closely and be prepared to adjust spend and messaging as the court's response to J&J's motion becomes clearer. Running aggressive volume campaigns into a potential adverse ruling without a clear litigation pathway is a risk management concern, not just a marketing one.
What Claimants Should Know
If you or a family member developed ovarian cancer or mesothelioma and used Johnson & Johnson talc-based products, this motion does not mean your claim has been dismissed. As of this writing, J&J has asked the court to consider dismissals — the court has not ruled. Existing filed claims remain on the docket pending judicial action.
However, developments like this reinforce why timing matters. If you have not yet spoken with a plaintiff attorney about a potential talc claim, waiting increases the risk that procedural developments or statutes of limitations could affect your options. The litigation landscape is changing rapidly, and individual claimants benefit from having their own counsel independent of MDL collective proceedings.
Do not make decisions about your claim based on news coverage alone. Speak directly with a qualified plaintiff attorney who handles talc or toxic tort cases.
Sources
Mass Tort Ad Agency is a plaintiff-side advertising agency, not a law firm. Nothing in this article is legal advice.